Altea Therapeutics

15 articles about Altea Therapeutics

• $60 Million Later, Biotech Altea Therapeutics Calls it Quits

  12/12/2011

• Altea Therapeutics and KAI Pharmaceuticals, Inc. Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides

  1/13/2010

• Altea Therapeutics Announces Senior R&D Management Appointments to Align Product Development with Needs of Commercialization Partners

  5/5/2009

• Altea Therapeutics Announces Development and Commercialization Agreement with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company for an Investigational Transdermal Exenatide

  4/1/2009

• Altea Therapeutics Forms Premier Scientific Advisory Board

  8/8/2008

• Altea Therapeutics and Hospira, Inc. Enter into Development and Commercialization Agreement for Transdermal Product; Altea Could Receive Milestone Payments up to $109M and Royalties

  7/2/2008

• Altea Therapeutics Appoints Dr. Richard H. Guy to its Scientific Advisory Board

  2/13/2008

• UCB Group, Altea Therapeutics Leaders Elected Georgia Bio Co-Chairs for 2008

  12/17/2007

• Altea Therapeutics Achieves Successful Transdermal Delivery of Therapeutic Carbohydrate Macromolecules; Signs Research Agreement with Major Pharmaceutical Company

  5/3/2007

• Frost & Sullivan Commends Altea Therapeutics for Extending the Frontiers of Transdermal Drug Delivery

  4/3/2007

• Altea Therapeutics Appoints Dr. William R. Good To Its Board Of Directors

  2/7/2007

• Altea Therapeutics Announces Positive Clinical Results For Its Basal Insulin Transdermal Patch

  1/25/2007

• Altea Therapeutics And Teikoku Seiyaku Co. Ltd. Enter Into Agreement For A New Transdermal Therapy For Parkinson's Disease

  2/1/2006

• Altea Therapeutics Appoints R. Gary Gilmore As Chief Financial Officer And Promotes Rick Hancock To Chief Operating Officer

  1/24/2006

• Altea Therapeutics To Receive 2006 GBP Deal Of Year Honors

  12/29/2005